×
Please click
here
if you are not redirected within a few seconds.
All
News
Images
Maps
Videos
Shopping
Books
Search tools
Recent
Recent
Past hour
Past 24 hours
Past week
Past month
Past year
Archives
Sorted by relevance
Sorted by relevance
Sorted by date
Mersana Therapeutics Provides Business Update and Announces First Quarter 2024 Financial Results
Yahoo Finance
Maximum tolerated dose not yet established in Phase 1 clinical trial of XMT-1660; enrollment in dose escalation and backfill cohorts...
1 day ago
Form 424B5 Mersana Therapeutics,
StreetInsider
Filed Pursuant to Rule 424(b)(5) Registration No. 333-271766. PROSPECTUS SUPPLEMENT (To Prospectus Dated May 9, 2024). $100,000,000.
1 day ago
Earnings call: Mersana Therapeutics outlines clinical progress By Investing.com
Investing.com
Mersana Therapeutics (NASDAQ:MRSN), in its first quarter 2024 earnings call, provided an update on its proprietary platforms and product...
1 day ago
Mersana Therapeutics, Inc. (NASDAQ:MRSN) Q1 2024 Earnings Call Transcript
Insider Monkey
Operator: Good morning, and welcome to the Mersana Therapeutics First Quarter 2024 Conference Call and Webcast.
9 hours ago
Mersana Therapeutics, Inc. 2024 Q1 - Results - Earnings Call Presentation (NASDAQ:MRSN)
Seeking Alpha
The following slide deck was published by Mersana Therapeutics, Inc. in conjunction with their 2024 Q1 earnings call.
1 day ago
Mersana Therapeutics reports Q1 EPS (16c), consensus (18c) - TipRanks.com
Tipranks
Mersana continues to advance its Phase 1 clinical trial of XMT-1660, the company's lead Dolasynthen ADC candidate targeting B7-H4.
1 day ago
Mersana Therapeutics Target of Unusually High Options Trading (NASDAQ:MRSN)
Defense World
Read Mersana Therapeutics Target of Unusually High Options Trading (NASDAQ:MRSN) at Defense World.
24 hours ago
Mersana Therapeutics, Inc. (MRSN) Reports Q1 Loss, Misses Revenue Estimates
Yahoo Finance
Mersana Therapeutics (MRSN) delivered earnings and revenue surprises of 11.11% and 5.18%, respectively, for the quarter ended March 2024.
1 day ago
It's a wrap for Merck KGaA and Mersana's 2014 ADC pact
Fierce Biotech
Mersana Therapeutics and Merck KGaA have severed ties for a licensing pact related to one of Mersana's ADC platforms.
4 months ago
Baird cuts Mersana shares target on Phase 1 study delay
Investing.com
On Friday, Baird adjusted its outlook on Mersana Therapeutics, Inc. (NASDAQ:MRSN) shares, reducing the price target to $4 from the previous...
16 hours ago